Drug Profile
Research programme: bicycle peptide therapeutics - AstraZeneca/Bicycle Therapeutics
Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Bicycle Therapeutics
- Developer AstraZeneca; Bicycle Therapeutics
- Class Cardiovascular therapies; Peptides
- Mechanism of Action Matrix metalloproteinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders; Metabolic disorders; Respiration disorders
Most Recent Events
- 31 Dec 2023 Bicycle Therapeutics terminates its collaborative agreement with Astrazeneca
- 31 Dec 2023 Discontinued - Preclinical for Respiration disorders in United Kingdom (Inhalation) before December 2023
- 31 Dec 2023 Discontinued for Cardiovascular disorders in United Kingdom (unspecified route) before December 2023